Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04164199 · ClinicalTrials.gov registry record · Phase 3
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
A Phase 3 study, sponsored by BeOne Medicines.
- Completed
- Registry status
- Phase 3
- Development phase
- 404
- Enrollment target
NCT04164199: Completed Phase 3 study, sponsored by BeOne Medicines.
NCT04164199 is a Phase 3 study that has completed, run by BeOne Medicines. The registered enrollment target is 404 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04164199, a Phase 3 study, has completed, sponsored by BeOne Medicines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 404 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).
Primary Outcome
Safety as assessed by the number of participants with immune-mediated adverse events (imAEs), ≥ Grade 3 adverse events, and serious adverse events.
Interventions
- DRUG Pamiparib
- DRUG Tislelizumab
- DRUG Temozolomide
- DRUG Ociperlimab
- DRUG Sitravatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2026-05-23 |
| Phase | Phase 3 |
What the finished NCT04164199 record still lists
NCT04164199 is an interventional study that assigns participants to a tested intervention. The registered 404 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 5 interventions - of which Pamiparib is the first listed.
NCT04164199 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04164199 about?
NCT04164199 is a clinical study titled "Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies". This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).
What is the current status of trial NCT04164199?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 404 participants. The study started on 2019-12-19. Estimated completion is 2026-05-23.
What interventions are being tested in trial NCT04164199?
The interventions under investigation include: Pamiparib (DRUG), Tislelizumab (DRUG), Temozolomide (DRUG), Ociperlimab (DRUG), Sitravatinib (DRUG).
Who is sponsoring clinical trial NCT04164199?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04164199's enrollment target sits among peer trials
404 914th of 2000 higher than 1,084 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
- NCT05611242 · 404 participants · Phase 3
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
- NCT06072612 · 404 participants · Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI